<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="9150">Simvastatin</z:chebi> is a competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme of the <z:chebi fb="0" ids="25350">mevalonate</z:chebi> pathway required for the biosynthesis of cholesterol and higher <z:chebi fb="0" ids="24913">isoprenoids</z:chebi> such as geranylgeranyl <z:chebi fb="2" ids="18361">pyrophosphate</z:chebi> (GGPP) </plain></SENT>
<SENT sid="1" pm="."><plain>Apart from its capacity to lower cholesterol plasma levels and to protect against <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e>, <z:chebi fb="0" ids="9150">simvastatin</z:chebi> induces <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in various <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells </plain></SENT>
<SENT sid="2" pm="."><plain>We have generated human Namalwa Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cells that display general <z:mpath ids='MPATH_3'>apoptosis</z:mpath> resistance and hyperproliferation due to increased expression and proteolytic activity of 26S proteasomes in response to continuous treatment of the cells with the <z:chebi fb="0" ids="52726">proteasome inhibitor</z:chebi> <z:chebi fb="0" ids="52717">bortezomib</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>In these cells, <z:chebi fb="0" ids="9150">simvastatin</z:chebi> does not inhibit proteasome activity, but induces <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, G2/M cell cycle arrest and accumulation of p21(Waf1/Cip1), and effectively inhibits hyperproliferation </plain></SENT>
<SENT sid="4" pm="."><plain>These effects are reversed by the addition of GGPP </plain></SENT>
<SENT sid="5" pm="."><plain>GGPP-dependent plasma membrane localization of the small GTPase RhoA that is required for RhoA-mediated oncogenic signaling is completely inhibited by <z:chebi fb="0" ids="9150">simvastatin</z:chebi> </plain></SENT>
<SENT sid="6" pm="."><plain>Finally, <z:chebi fb="0" ids="52717">bortezomib</z:chebi> but not <z:chebi fb="0" ids="9150">simvastatin</z:chebi> induces accumulation and stabilization of the anti-apoptotic protein Mcl-1, which is known to confer resistance to <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells </plain></SENT>
<SENT sid="7" pm="."><plain>Thus, <z:chebi fb="0" ids="9150">simvastatin</z:chebi> overcomes <z:chebi fb="0" ids="52717">bortezomib</z:chebi>-induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath> resistance by inhibiting synthesis of GGPP and disrupting a GGPP-dependent survival pathway </plain></SENT>
</text></document>